{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:37:33Z","timestamp":1794245853156,"version":"4.9.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41591-026-04481-9","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:03:34Z","timestamp":1782378214000},"page":"2918-2932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling"],"prefix":"10.1038","volume":"32","author":[{"given":"D\u00e9borah","family":"Suissa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-9688","authenticated-orcid":false,"given":"Marine","family":"Fidelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao-Nguyen","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9768-1946","authenticated-orcid":false,"given":"Johannes R.","family":"Bj\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kitaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00e9onore","family":"Piard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lebhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7808-8394","authenticated-orcid":false,"given":"Ai-Ling","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Thelemaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1920-142X","authenticated-orcid":false,"given":"Carolina","family":"Alves Costa Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8223-3697","authenticated-orcid":false,"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1739","authenticated-orcid":false,"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1583-5794","authenticated-orcid":false,"given":"Nicola","family":"Segata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-1817","authenticated-orcid":false,"given":"Gianmarco","family":"Piccinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3047-7892","authenticated-orcid":false,"given":"Geke A. P.","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-7779","authenticated-orcid":false,"given":"Saman","family":"Maleki Vareki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6225-3973","authenticated-orcid":false,"given":"John G.","family":"Lenehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4757-4565","authenticated-orcid":false,"given":"David","family":"Boulate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kuznetsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7928-7371","authenticated-orcid":false,"given":"Rinse K.","family":"Weersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Messaoudene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylv\u00e8re","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlijn M.","family":"van der Aalst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4682-3646","authenticated-orcid":false,"given":"Harry J.","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Schuler-Thurner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-4040","authenticated-orcid":false,"given":"I. Jolanda M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9158-3373","authenticated-orcid":false,"given":"Edmond","family":"Rafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e Maria","family":"Saliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-9922","authenticated-orcid":false,"given":"Marc","family":"Machaalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Porcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-2117","authenticated-orcid":false,"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-4841","authenticated-orcid":false,"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1981-1535","authenticated-orcid":false,"given":"Arielle","family":"Elkrief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-3643","authenticated-orcid":false,"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Chamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8318-0515","authenticated-orcid":false,"given":"Gianluca","family":"Ianiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1955-9149","authenticated-orcid":false,"given":"Bertrand","family":"Routy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9668-4763","authenticated-orcid":false,"given":"Nikos","family":"Paragios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-0998","authenticated-orcid":false,"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"4481_CR1","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","volume":"78","author":"JE Bader","year":"2020","unstructured":"Bader, J. E., Voss, K. & Rathmell, J. C. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol. Cell 78, 1019\u20131033 (2020).","journal-title":"Mol. Cell"},{"key":"4481_CR2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","volume":"169","author":"MD Buck","year":"2017","unstructured":"Buck, M. D., Sowell, R. T., Kaech, S. M. & Pearce, E. L. Metabolic Instruction of Immunity. Cell 169, 570\u2013586 (2017).","journal-title":"Cell"},{"key":"4481_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2021.12.012","volume":"55","author":"NM Chapman","year":"2022","unstructured":"Chapman, N. M. & Chi, H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity 55, 14\u201330 (2022).","journal-title":"Immunity"},{"key":"4481_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41573-025-01227-z","volume":"24","author":"MP Trefny","year":"2025","unstructured":"Trefny, M. P., Kroemer, G., Zitvogel, L. & Kobold, S. Metabolites as agents and targets for cancer immunotherapy. Nat. Rev. Drug Discov. 24, 764\u2013784 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4481_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nri.2017.99","volume":"18","author":"GR Bantug","year":"2018","unstructured":"Bantug, G. R., Galluzzi, L., Kroemer, G. & Hess, C. The spectrum of T cell metabolism in health and disease. Nat. Rev. Immunol. 18, 19\u201334 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"4481_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","volume":"36","author":"RIK Geltink","year":"2018","unstructured":"Geltink, R. I. K., Kyle, R. L. & Pearce, E. L. Unraveling the complex interplay between T cell metabolism and function. Annu. Rev. Immunol. 36, 461\u2013488 (2018).","journal-title":"Annu. Rev. Immunol."},{"key":"4481_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/ni.2386","volume":"13","author":"R Wang","year":"2012","unstructured":"Wang, R. & Green, D. R. Metabolic checkpoints in activated T cells. Nat. Immunol. 13, 907\u2013915 (2012).","journal-title":"Nat. Immunol."},{"key":"4481_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma, X. et al. Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell Metab. 30, 143\u2013156.e5 (2019).","journal-title":"Cell Metab."},{"key":"4481_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/imr.13215","volume":"317","author":"Z You","year":"2023","unstructured":"You, Z. & Chi, H. Lipid metabolism in dendritic cell biology. Immunol. Rev. 317, 137\u2013151 (2023).","journal-title":"Immunol. Rev."},{"key":"4481_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41586-023-06483-w","volume":"621","author":"M Reina-Campos","year":"2023","unstructured":"Reina-Campos, M. et al. Metabolic programs of T cell tissue residency empower tumour immunity. Nature 621, 179\u2013187 (2023).","journal-title":"Nature"},{"key":"4481_CR11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.chembiol.2024.02.001","volume":"31","author":"NM Chapman","year":"2024","unstructured":"Chapman, N. M. & Chi, H. Metabolic rewiring and communication in cancer immunity. Cell Chem. Biol. 31, 862\u2013883 (2024).","journal-title":"Cell Chem. Biol."},{"key":"4481_CR12","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","volume":"25","author":"CC Zebley","year":"2024","unstructured":"Zebley, C. C., Zehn, D., Gottshalk, S. & Chi, H. T cell dysfunction and therapeutic intervention in cancer. Nat. Immunol. 25, 1344\u20131354 (2024).","journal-title":"Nat. Immunol."},{"key":"4481_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s43018-022-00506-7","volume":"4","author":"DK Lester","year":"2023","unstructured":"Lester, D. K. et al. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat. Cancer 4, 222\u2013239 (2023).","journal-title":"Nat. Cancer"},{"key":"4481_CR14","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang, C.-H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229\u20131241 (2015).","journal-title":"Cell"},{"key":"4481_CR15","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1182\/blood-2009-10-249540","volume":"115","author":"CM Krawczyk","year":"2010","unstructured":"Krawczyk, C. M. et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115, 4742\u20134749 (2010).","journal-title":"Blood"},{"key":"4481_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nri3701","volume":"14","author":"KN Pollizzi","year":"2014","unstructured":"Pollizzi, K. N. & Powell, J. D. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat. Rev. Immunol. 14, 435\u2013446 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"4481_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ccell.2017.10.003","volume":"32","author":"A Palazon","year":"2017","unstructured":"Palazon, A. et al. An HIF-1\u03b1\/VEGF-A axis in cytotoxic T cells regulates tumor progression. Cancer Cell 32, 669\u2013683.e5 (2017).","journal-title":"Cancer Cell"},{"key":"4481_CR18","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1158\/0008-5472.CAN-15-1538","volume":"76","author":"S Lim","year":"2016","unstructured":"Lim, S. et al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1\u03b1. Cancer Res. 76, 2231\u20132242 (2016).","journal-title":"Cancer Res."},{"key":"4481_CR19","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","volume":"27","author":"T Cascone","year":"2018","unstructured":"Cascone, T. et al. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab. 27, 977\u2013987.e4 (2018).","journal-title":"Cell Metab."},{"key":"4481_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145207","volume":"6","author":"G Ferrere","year":"2021","unstructured":"Ferrere, G. et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight 6, e145207 (2021). 145207.","journal-title":"JCI Insight"},{"key":"4481_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595\u2013602 (2021).","journal-title":"Science"},{"key":"4481_CR22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602\u2013609 (2021).","journal-title":"Science"},{"key":"4481_CR23","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. 29, 2121\u20132132 (2023).","journal-title":"Nat. Med."},{"key":"4481_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000186","volume":"8","author":"D Allard","year":"2020","unstructured":"Allard, D., Allard, B. & Stagg, J. On the mechanism of anti-CD39 immune checkpoint therapy. J. Immunother. Cancer 8, e000186 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"4481_CR25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-4264","author":"PD Zang","year":"2025","unstructured":"Zang, P. D. & Dorff, T. B. IDO believe in immunotherapy. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-4264 (2025).","journal-title":"Clin. Cancer Res."},{"key":"4481_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ygyno.2024.06.017","volume":"188","author":"MR Mirza","year":"2024","unstructured":"Mirza, M. R. et al. NSGO-OV-UMB1\/ENGOT-OV30: a phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody oleclumab in patients with relapsed ovarian cancer. Gynecol. Oncol. 188, 103\u2013110 (2024).","journal-title":"Gynecol. Oncol."},{"key":"4481_CR27","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/4551054a","volume":"455","author":"JK Nicholson","year":"2008","unstructured":"Nicholson, J. K. & Lindon, J. C. Systems biology: metabonomics. Nature 455, 1054\u20131056 (2008).","journal-title":"Nature"},{"key":"4481_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/msb.2011.57","volume":"7","author":"G Nicholson","year":"2011","unstructured":"Nicholson, G. et al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol. Syst. Biol. 7, 525 (2011).","journal-title":"Mol. Syst. Biol."},{"key":"4481_CR29","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1021\/acs.jproteome.5b00275","volume":"14","author":"V Ghini","year":"2015","unstructured":"Ghini, V., Saccenti, E., Tenori, L., Assfalg, M. & Luchinat, C. Allostasis and resilience of the human individual metabolic phenotype. J. Proteome Res. 14, 2951\u20132962 (2015).","journal-title":"J. Proteome Res."},{"key":"4481_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.678753","volume":"8","author":"X Nie","year":"2021","unstructured":"Nie, X. et al. Serum metabolite biomarkers predictive of response to PD-1 blockade therapy in non-small cell lung cancer. Front. Mol. Biosci. 8, 678753 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"4481_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45357-1","volume":"15","author":"C Alves Costa Silva","year":"2024","unstructured":"Alves Costa Silva, C. et al. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial. Nat. Commun. 15, 1633 (2024).","journal-title":"Nat. Commun."},{"key":"4481_CR32","doi-asserted-by":"publisher","first-page":"e008190","DOI":"10.1136\/jitc-2023-008190","volume":"12","author":"L Zheng","year":"2024","unstructured":"Zheng, L. et al. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. J. Immunother. Cancer 12, e008190 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"4481_CR33","doi-asserted-by":"publisher","first-page":"6932","DOI":"10.3390\/ijms22136932","volume":"22","author":"SJ Yoon","year":"2021","unstructured":"Yoon, S. J., Lee, C. B., Chae, S. U., Jo, S. J. & Bae, S. K. The comprehensive \u2018omics\u2019 approach from metabolomics to advanced omics for development of immune checkpoint inhibitors: potential strategies for next generation of cancer immunotherapy. Int. J. Mol. Sci. 22, 6932 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"4481_CR34","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.3390\/cancers12123574","volume":"12","author":"V Ghini","year":"2020","unstructured":"Ghini, V. et al. Metabolomics to assess response to immune checkpoint inhibitors in patients with non-small-cell lung cancer. Cancers 12, 3574 (2020).","journal-title":"Cancers"},{"key":"4481_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12361-9","volume":"10","author":"H Li","year":"2019","unstructured":"Li, H. et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat. Commun. 10, 4346 (2019).","journal-title":"Nat. Commun."},{"key":"4481_CR36","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1177\/09622802231206477","volume":"32","author":"A Devaux","year":"2023","unstructured":"Devaux, A., Helmer, C., Genuer, R. & Proust-Lima, C. Random survival forests with multivariate longitudinal endogenous covariates. Stat. Methods Med. Res. 32, 2331\u20132346 (2023).","journal-title":"Stat. Methods Med. Res."},{"key":"4481_CR37","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-025-03608-8","volume":"31","author":"L Zitvogel","year":"2025","unstructured":"Zitvogel, L. et al. Impact of the ONCOBIOME network in cancer microbiome research. Nat. Med. 31, 1085\u20131098 (2025).","journal-title":"Nat. Med."},{"key":"4481_CR38","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41591-024-02803-3","volume":"30","author":"JR Bj\u00f6rk","year":"2024","unstructured":"Bj\u00f6rk, J. R. et al. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nat. Med. 30, 785\u2013796 (2024).","journal-title":"Nat. Med."},{"key":"4481_CR39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","volume":"28","author":"KA Lee","year":"2022","unstructured":"Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535\u2013544 (2022).","journal-title":"Nat. Med."},{"key":"4481_CR40","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4481_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2484880","volume":"14","author":"R Birebent","year":"2025","unstructured":"Birebent, R. et al. Surrogate markers of intestinal dysfunction associated with survival in advanced cancers. OncoImmunology 14, 2484880 (2025).","journal-title":"OncoImmunology"},{"key":"4481_CR42","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.ccell.2024.06.009","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell 42, 1268\u20131285.e7 (2024).","journal-title":"Cancer Cell"},{"key":"4481_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01970-8","volume":"23","author":"A Levy","year":"2024","unstructured":"Levy, A. et al. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer. Mol. Cancer 23, 61 (2024).","journal-title":"Mol. Cancer"},{"key":"4481_CR44","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1158\/2159-8290.CD-22-0201","volume":"12","author":"A-G Goubet","year":"2022","unstructured":"Goubet, A.-G. et al. Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. Cancer Discov 12, 2280\u20132307 (2022).","journal-title":"Cancer Discov"},{"key":"4481_CR45","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti, C. et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 23, 876\u2013887 (2022).","journal-title":"Lancet Oncol."},{"key":"4481_CR46","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","volume":"22","author":"RJ Motzer","year":"2004","unstructured":"Motzer, R. J. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. JCO 22, 454\u2013463 (2004).","journal-title":"JCO"},{"key":"4481_CR47","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1001\/jama.2011.574","volume":"305","author":"K Stolarz-Skrzypek","year":"2011","unstructured":"Stolarz-Skrzypek, K. et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA 305, 1777\u20131785 (2011).","journal-title":"JAMA"},{"key":"4481_CR48","doi-asserted-by":"publisher","first-page":"12905","DOI":"10.3390\/ijms252312905","volume":"25","author":"E Santana","year":"2024","unstructured":"Santana, E., Ibrahimi, E., Ntalianis, E., Cauwenberghs, N. & Kuznetsova, T. Integrating metabolomics domain knowledge with explainable machine learning in atherosclerotic cardiovascular disease classification. Int. J. Mol. Sci. 25, 12905 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"4481_CR49","doi-asserted-by":"publisher","first-page":"e067191","DOI":"10.1136\/bmjopen-2022-067191","volume":"12","author":"D Boulate","year":"2022","unstructured":"Boulate, D. et al. Epidemiological study to assess the prevalence of lung cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol. BMJ Open 12, e067191 (2022).","journal-title":"BMJ Open"},{"key":"4481_CR50","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/ehjci\/jeaa168","volume":"21","author":"CM van der Aalst","year":"2020","unstructured":"van der Aalst, C. M. et al. Screening for cardiovascular disease risk using traditional risk factor assessment or coronary artery calcium scoring: the ROBINSCA trial. Eur. Heart J. Cardiovasc. Imaging 21, 1216\u20131224 (2020).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"4481_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04186-5","author":"S Duttagupta","year":"2026","unstructured":"Duttagupta, S. et al. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-04186-5 (2026).","journal-title":"Nat. Med."},{"key":"4481_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04189-2","author":"S Porcari","year":"2026","unstructured":"Porcari, S. et al. Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-04189-2 (2026).","journal-title":"Nat. Med."},{"key":"4481_CR53","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/bjd\/ljaf350","volume":"194","author":"S Haferkamp","year":"2026","unstructured":"Haferkamp, S. et al. Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial. Br. J. Dermatol. 194, 216\u2013224 (2026).","journal-title":"Br. J. Dermatol."},{"key":"4481_CR54","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jaci.2011.06.051","volume":"128","author":"L O\u2019Mahony","year":"2011","unstructured":"O\u2019Mahony, L., Akdis, M. & Akdis, C. A. Regulation of the immune response and inflammation by histamine and histamine receptors. J. Allergy Clin. Immunol. 128, 1153\u20131162 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"4481_CR55","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1113\/JP283261","volume":"601","author":"V Flores","year":"2023","unstructured":"Flores, V. et al. Regulation of metabolic health by dietary histidine in mice. J. Physiol. 601, 2139\u20132163 (2023).","journal-title":"J. Physiol."},{"key":"4481_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/srep15356","volume":"5","author":"R Liao","year":"2015","unstructured":"Liao, R. et al. Histidine provides long-term neuroprotection after cerebral ischemia through promoting astrocyte migration. Sci. Rep. 5, 15356 (2015).","journal-title":"Sci. Rep."},{"key":"4481_CR57","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-025-09263-w","volume":"645","author":"A Mastrangelo","year":"2025","unstructured":"Mastrangelo, A. et al. Imidazole propionate is a driver and therapeutic target in atherosclerosis. Nature 645, 254\u2013261 (2025).","journal-title":"Nature"},{"key":"4481_CR58","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3945\/jn.114.196105","volume":"144","author":"T Yoshikawa","year":"2014","unstructured":"Yoshikawa, T. et al. Insufficient intake of L-histidine reduces brain histamine and causes anxiety-like behaviors in male mice. J. Nutr. 144, 1637\u20131641 (2014).","journal-title":"J. Nutr."},{"key":"4481_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/science.abo2296","volume":"380","author":"M Fidelle","year":"2023","unstructured":"Fidelle, M. et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science 380, eabo2296 (2023).","journal-title":"Science"},{"key":"4481_CR60","doi-asserted-by":"publisher","first-page":"13347","DOI":"10.1073\/pnas.1804149115","volume":"115","author":"N Ron-Harel","year":"2018","unstructured":"Ron-Harel, N. et al. Defective respiration and one-carbon metabolism contribute to impaired na\u00efve T cell activation in aged mice. Proc. Natl Acad. Sci. USA 115, 13347\u201313352 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4481_CR61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103730118","volume":"118","author":"Y Nakajima","year":"2021","unstructured":"Nakajima, Y., Chamoto, K., Oura, T. & Honjo, T. Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice. Proc. Natl Acad. Sci. USA 118, e2103730118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4481_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100732","volume":"2","author":"L Zhao","year":"2021","unstructured":"Zhao, L. et al. A genotype-phenotype screening system using conditionally immortalized immature dendritic cells. STAR Protoc. 2, 100732 (2021).","journal-title":"STAR Protoc."},{"key":"4481_CR63","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1200\/JCO.2025.43.16_suppl.2567","volume":"43","author":"E Rafie","year":"2025","unstructured":"Rafie, E. et al. Dietary compounds and patterns associated with immune checkpoint inhibitor (ICI) outcomes in advanced non-small cell lung cancer (NSCLC). JCO 43, 2567\u20132567 (2025).","journal-title":"JCO"},{"key":"4481_CR64","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1017\/S1368980016001099","volume":"19","author":"CL Cleghorn","year":"2016","unstructured":"Cleghorn, C. L. et al. Can a dietary quality score derived from a short-form FFQ assess dietary quality in UK adult population surveys? Public Health Nutr. 19, 2915\u20132923 (2016).","journal-title":"Public Health Nutr."},{"key":"4481_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-018-0355-9","volume":"17","author":"S Morel","year":"2018","unstructured":"Morel, S. et al. Development and relative validation of a food frequency questionnaire for French-Canadian adolescent and young adult survivors of acute lymphoblastic leukemia. Nutr. J. 17, 45 (2018).","journal-title":"Nutr. J."},{"key":"4481_CR66","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","volume":"187","author":"L Derosa","year":"2024","unstructured":"Derosa, L. et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell 187, 3373\u20133389.e16 (2024).","journal-title":"Cell"},{"key":"4481_CR67","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41422-025-01212-6","volume":"36","author":"AA Almonte","year":"2026","unstructured":"Almonte, A. A. et al. Gut dysbiosis in oncology: a risk factor for immunoresistance. Cell Res. 36, 103\u2013120 (2026).","journal-title":"Cell Res."},{"key":"4481_CR68","doi-asserted-by":"publisher","first-page":"S707","DOI":"10.1016\/j.annonc.2024.08.1126","volume":"35","author":"A Elkrief","year":"2024","unstructured":"Elkrief, A. et al. 1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate). Ann. Oncol. 35, S707\u2013S708 (2024).","journal-title":"Ann. Oncol."},{"key":"4481_CR69","doi-asserted-by":"publisher","first-page":"9544","DOI":"10.1200\/JCO.2023.41.16_suppl.9544","volume":"41","author":"L Heinzerling","year":"2023","unstructured":"Heinzerling, L. et al. Breaking primary checkpoint inhibitor resistance: Interim analysis of a multicenter phase II study by intermittent application of an alkylating agent among patients with metastatic melanoma. JCO 41, 9544\u20139544 (2023).","journal-title":"JCO"},{"key":"4481_CR70","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.3390\/cancers14133282","volume":"14","author":"D Tomsitz","year":"2022","unstructured":"Tomsitz, D. et al. Development of lymphopenia during therapy with immune checkpoint inhibitors is associated with poor outcome in metastatic cutaneous melanoma. Cancers 14, 3282 (2022).","journal-title":"Cancers"},{"key":"4481_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2022.108676","volume":"45","author":"TU Schulz","year":"2022","unstructured":"Schulz, T. U. et al. Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: a large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases. Data Brief. 45, 108676 (2022).","journal-title":"Data Brief."},{"key":"4481_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04183-8","author":"R Fernandes","year":"2026","unstructured":"Fernandes, R. et al. Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-04183-8 (2026).","journal-title":"Nat. Med."},{"key":"4481_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00878-z","volume":"29","author":"C-C Kuo","year":"2022","unstructured":"Kuo, C.-C., Wu, J.-Y. & Wu, K. K. Cancer-derived extracellular succinate: a driver of cancer metastasis. J. Biomed. Sci. 29, 93 (2022).","journal-title":"J. Biomed. Sci."},{"key":"4481_CR74","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.molcel.2019.10.023","volume":"77","author":"J-Y Wu","year":"2020","unstructured":"Wu, J.-Y. et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol. Cell 77, 213\u2013227.e5 (2020).","journal-title":"Mol. Cell"},{"key":"4481_CR75","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.tcb.2013.11.008","volume":"24","author":"E Mills","year":"2014","unstructured":"Mills, E. & O\u2019Neill, L. A. J. Succinate: a metabolic signal in inflammation. Trends Cell Biol. 24, 313\u2013320 (2014).","journal-title":"Trends Cell Biol."},{"key":"4481_CR76","doi-asserted-by":"publisher","first-page":"1266973","DOI":"10.3389\/fcell.2023.1266973","volume":"11","author":"W Zhang","year":"2023","unstructured":"Zhang, W. & Lang, R. Succinate metabolism: a promising therapeutic target for inflammation, ischemia\/reperfusion injury and cancer. Front. Cell Dev. Biol. 11, 1266973 (2023).","journal-title":"Front. Cell Dev. Biol."},{"key":"4481_CR77","doi-asserted-by":"publisher","first-page":"885093","DOI":"10.3389\/fcimb.2022.885093","volume":"12","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. Combined microbiome and metabolome analysis reveals a novel interplay between intestinal flora and serum metabolites in lung cancer. Front. Cell. Infect. Microbiol. 12, 885093 (2022).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"4481_CR78","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000015483","volume":"88","author":"A Solans","year":"2000","unstructured":"Solans, A., Estivill, X. & de la Luna, S. Cloning and characterization of human FTCD on 21q22.3, a candidate gene for glutamate formiminotransferase deficiency. Cytogenet. Cell Genet. 88, 43\u201349 (2000).","journal-title":"Cytogenet. Cell Genet."},{"key":"4481_CR79","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13075-018-1729-2","volume":"20","author":"XM Teitsma","year":"2018","unstructured":"Teitsma, X. M. et al. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology. Arthritis Res. Ther. 20, 230 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"4481_CR80","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41586-018-0316-7","volume":"559","author":"N Kanarek","year":"2018","unstructured":"Kanarek, N. et al. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature 559, 632\u2013636 (2018).","journal-title":"Nature"},{"key":"4481_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06267-y","volume":"23","author":"P Liu","year":"2025","unstructured":"Liu, P. et al. Histidine metabolism drives liver cancer progression via immune microenvironment modulation through metabolic reprogramming. J. Transl. Med. 23, 262 (2025).","journal-title":"J. Transl. Med"},{"key":"4481_CR82","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccell.2021.11.002","volume":"40","author":"H Li","year":"2022","unstructured":"Li, H. et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell 40, 36\u201352.e9 (2022).","journal-title":"Cancer Cell"},{"key":"4481_CR83","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.stem.2022.09.009","volume":"29","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Glioblastoma stem cell-specific histamine secretion drives pro-angiogenic tumor microenvironment remodeling. Cell Stem Cell 29, 1531\u20131546.e7 (2022).","journal-title":"Cell Stem Cell"},{"key":"4481_CR84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccell.2021.11.007","volume":"40","author":"S Chen","year":"2022","unstructured":"Chen, S. & Luster, A. D. Antihistamines for cancer immunotherapy: more than just treating allergies. Cancer Cell 40, 9\u201311 (2022).","journal-title":"Cancer Cell"},{"key":"4481_CR85","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2337\/dc24-2816","volume":"48","author":"H Yang","year":"2025","unstructured":"Yang, H. et al. Diet, gut microbiota, and histidine metabolism toward imidazole propionate production in relation to type 2 diabetes. Diabetes Care 48, 1225\u20131232 (2025).","journal-title":"Diabetes Care"},{"key":"4481_CR86","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1056\/NEJM197412052912303","volume":"291","author":"HL Levy","year":"1974","unstructured":"Levy, H. L., Shih, V. E. & Madigan, P. M. Routine newborn screening for histidinemia. Clinical and biochemical results. N. Engl. J. Med. 291, 1214\u20131219 (1974).","journal-title":"N. Engl. J. Med."},{"key":"4481_CR87","first-page":"14","volume":"18","author":"KE Glinton","year":"2018","unstructured":"Glinton, K. E., Levy, H. L., Kennedy, A. D., Pappan, K. L. & Elsea, S. H. Untargeted metabolomics identifies unique though benign biochemical changes in patients with pathogenic variants in UROC1. Mol. Genet. Metab. Rep. 18, 14\u201318 (2018).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"4481_CR88","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/jimd.12035","volume":"42","author":"RC Ahrens-Nicklas","year":"2019","unstructured":"Ahrens-Nicklas, R. C., Ganetzky, R. D., Rush, P. W., Conway, R. L. & Ficicioglu, C. Characteristics and outcomes of patients with formiminoglutamic aciduria detected through newborn screening. J. Inherit. Metab. Dis. 42, 140\u2013146 (2019).","journal-title":"J. Inherit. Metab. Dis."},{"key":"4481_CR89","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF02338970","volume":"6","author":"CR Scriver","year":"1983","unstructured":"Scriver, C. R. & Levy, H. L. Histidinaemia. Part I: reconciling retrospective and prospective findings. J. Inherit. Metab. Dis. 6, 51\u201353 (1983).","journal-title":"J. Inherit. Metab. Dis."},{"key":"4481_CR90","doi-asserted-by":"publisher","first-page":"6205","DOI":"10.1021\/ja01604a069","volume":"78","author":"HP Broquist","year":"1956","unstructured":"Broquist, H. P. Evidence for the excretion of formimino-glutamic acid following folic acid antagonist therapy in acute leukemia. J. Am. Chem. Soc. 78, 6205\u20136206 (1956).","journal-title":"J. Am. Chem. Soc."},{"key":"4481_CR91","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2370616","volume":"16","author":"MV Warmbrunn","year":"2024","unstructured":"Warmbrunn, M. V. et al. Oral histidine affects gut microbiota and MAIT cells improving glycemic control in type 2 diabetes patients. Gut Microbes 16, 2370616 (2024).","journal-title":"Gut Microbes"},{"key":"4481_CR92","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/ajcn\/nqaa210","volume":"112","author":"ME Gheller","year":"2020","unstructured":"Gheller, M. E. et al. Tolerance to graded dosages of histidine supplementation in healthy human adults. Am. J. Clin. Nutr. 112, 1358\u20131367 (2020).","journal-title":"Am. J. Clin. Nutr."},{"key":"4481_CR93","doi-asserted-by":"publisher","first-page":"e000898","DOI":"10.1136\/openhrt-2018-000898","volume":"5","author":"JJ DiNicolantonio","year":"2018","unstructured":"DiNicolantonio, J. J. & O\u2019Keefe, J. H. Omega-6 vegetable oils as a driver of coronary heart disease: the oxidized linoleic acid hypothesis. Open Heart 5, e000898 (2018).","journal-title":"Open Heart"},{"key":"4481_CR94","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/nu12030848","volume":"12","author":"M Hole\u010dek","year":"2020","unstructured":"Hole\u010dek, M. Histidine in health and disease: metabolism, physiological importance, and use as a supplement. Nutrients 12, 848 (2020).","journal-title":"Nutrients"},{"key":"4481_CR95","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/CCID.S146760","volume":"10","author":"SP Tan","year":"2017","unstructured":"Tan, S. P., Brown, S. B., Griffiths, C. E., Weller, R. B. & Gibbs, N. K. Feeding filaggrin: effects of l-histidine supplementation in atopic dermatitis. Clin. Cosmet. Investig. Dermatol. 10, 403\u2013411 (2017).","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"4481_CR96","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/jcp.15.3.269","volume":"15","author":"I Chanarin","year":"1962","unstructured":"Chanarin, I., Bennett, M. C. & Berry, V. Urinary excretion of histidine derivatives in megaloblastic anaemia and other conditions and comparison with the folic acid clearance test. J. Clin. Pathol. 15, 269\u2013273 (1962).","journal-title":"J. Clin. Pathol."},{"key":"4481_CR97","doi-asserted-by":"publisher","unstructured":"Gheller, M., Bender, E. & Thalacker-Mercer, A. Safety of graded-doses of histidine in healthy adults (P08-062-19). Curr. Dev. Nutr. https:\/\/doi.org\/10.1093\/cdn\/nzz044.P08-062-19 (2019).","DOI":"10.1093\/cdn\/nzz044.P08-062-19"},{"key":"4481_CR98","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.18632\/aging.202739","volume":"13","author":"C Grajeda-Iglesias","year":"2021","unstructured":"Grajeda-Iglesias, C. et al. Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites. Aging 13, 6375\u20136405 (2021).","journal-title":"Aging"},{"key":"4481_CR99","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.mcb.2021.04.001","volume":"164","author":"S Durand","year":"2021","unstructured":"Durand, S. et al. The intracellular metabolome of starving cells. Methods Cell. Biol. 164, 137\u2013156 (2021).","journal-title":"Methods Cell. Biol."},{"key":"4481_CR100","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd7064","volume":"13","author":"M Abdellatif","year":"2021","unstructured":"Abdellatif, M. et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci. Transl. Med. 13, eabd7064 (2021).","journal-title":"Sci. Transl. Med."},{"key":"4481_CR101","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbad260","volume":"24","author":"Q Blampey","year":"2023","unstructured":"Blampey, Q. et al. A biology-driven deep generative model for cell-type annotation in cytometry. Brief. Bioinform. 24, bbad260 (2023).","journal-title":"Brief. Bioinform."},{"key":"4481_CR102","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk, J. A. et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell 40, 768\u2013786.e7 (2022).","journal-title":"Cancer Cell"},{"key":"4481_CR103","doi-asserted-by":"publisher","first-page":"e62621","DOI":"10.1371\/journal.pone.0062621","volume":"8","author":"C Richter","year":"2013","unstructured":"Richter, C. et al. Generation of inducible immortalized dendritic cells with proper immune function in vitro and in vivo. PLoS ONE 8, e62621 (2013).","journal-title":"PLoS ONE"},{"key":"4481_CR104","doi-asserted-by":"publisher","unstructured":"Fidelle, M. et al. Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling. Mendeley Data https:\/\/doi.org\/10.17632\/fjp66dc7p4.1 (2026).","DOI":"10.17632\/fjp66dc7p4.1"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04481-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04481-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04481-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:01:30Z","timestamp":1786629690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04481-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":104,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4481"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04481-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L. Zitvogel is the founder and Scientific Advisory Board President of EverImmune and has received research grant support from Daiichi Sankyo, Pileje, Biom\u00e9rieux and EverImmune. G.K. holds research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys and Vascage. G.K. serves on the Board of Directors of the Bristol Myers Squibb Foundation France and is a scientific co-founder of EverImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. G.K. is a member of the scientific advisory boards of Hevolution, Institut Servier, and Rejuveron Life Sciences\/Centenara Labs. G.K. is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. G.K.\u2019s brother, R. Kroemer, was previously employed by Sanofi and currently consults for Boehringer Ingelheim. N.P. is an employee and stockholder at TheraPancea, and a board member and stockholder at Artedrone and Nuclivision. N.P. is also a scientific advisor and stockholder at Reveal Genomics. L.H. has received advisory board fees from Bristol Myers Squibb, Immunocore, Merck Sharp & Dohme, Novartis and Therakos. L.H.\u2019s institution conducts clinical trials sponsored by Agenus, AstraZeneca, Bristol Myers Squibb, Huya Bioscience International, Immunocore Limited, IO Biotech, Merck Sharp & Dohme, PamGene International B.V., Pfizer, Pierre Fabre, Regeneron, Replimune and Sol-Gel Technologies. G.A.P.H. has received institutional research grants from SEERAVE and Bristol Myers Squibb, and institutional consulting fees from Bristol Myers Squibb, Roche, MSD, Novartis, Sanofi, Pierre Fabre and Amgen. A.E. declares grant support from Kanvas Bioscience, GMT Science, AstraZeneca, Merck and Bristol Myers Squibb, and honoraria from AstraZeneca, Merck, Bristol Myers Squibb and EMD Serono. A.E. is an inventor on patent 4872-8531-1934.1 related to the microbiome and immunotherapy response. B.R. has received research funding from Davolterra and Kanvas Bioscience, consulting fees from Merck, AstraZeneca, Vendata and Bristol Myers Squibb, and is a co-founder of Curebiota. L.D. serves on advisory boards for AstraZeneca, Sanofi, Bristol Myers Squibb, Roche and EverImmune. R.K.W. has acted as a consultant for Takeda; received unrestricted research grants from Takeda, Johnson & Johnson, Tramedico and Ferring; and received speaker fees from MSD, Falk, AbbVie and Janssen Pharmaceuticals. E.D. reports grants and personal fees from Roche-Genentech, AstraZeneca, Merck Serono, Boehringer Ingelheim, Bristol Myers Squibb and MSD. S.M.V. reports a grant from Microviable Therapeutics (outside the submitted work), consulting fees from Kanvas Bioscience and FedBio, and is a co-inventor (with M.S.S.) on US Patent application no. 63\/913,940 related to FMT donor screening. Y.L. reports grants from MSD; personal fees from MSD, Bristol Myers Squibb, Pfizer, Merck Serono, AstraZeneca, Seattle Genetics, Gilead, Taiho and Astellas; grants and personal fees from Janssen; and grants from Roche and Celsius. N.S. is a founder and shareholder of PreBiomics and a member of the scientific advisory board of ZOE, and has received consultancy fees from both. M. Machaalani reports institutional research funding from Genentech\/imCORE. M.S.S. is a co-founder of LND Therapeutics, which holds the rights to LND101, and is a co-inventor (with S.M.V.) on US Patent application no. 63\/913,940 related to FMT donor screening. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}